SION Stock Analysis: Buy, Sell, or Hold?
SION - Sionna Therapeutics, Inc. Common Stock
$36.18
0.26 (0.72%)
▲
5d:
+7.97%
30d:
-15.41%
90d:
-2.66%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Get Alerted When SION Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SION shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SION shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SION is currently trading at $36.18, which is considered slightly low relative to its 30-day fair value range of $36.03 to $43.11.
Technical Outlook: Technically, SION is showing sideways momentum. Immediate support is located at $32.26, while resistance sits at $42.07.
Market Sentiment: SION has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.60 (+43.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SION is showing sideways momentum. Immediate support is located at $32.26, while resistance sits at $42.07.
Market Sentiment: SION has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (12th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $51.60 (+43.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$36.03 -
$43.11
Company Quality Score
49/100
(HOLD)
Options IV Signal
12th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 12th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.7% below Wall St target ($51.60)
Trading Range Analysis
30-Day Trading Range
$36.03 -
$43.11
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$5.37
(14.9%)
Support & Resistance Levels
Support Level
$32.26
Resistance Level
$42.07
Current Trend
Sideways
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.82
Wall Street Target
$51.60
(+43.7%)
Share & Embed Analysis
Last updated: June 15, 2026 10:41 AM ET
Data refreshes hourly during market hours. Next update: 11:41 AM
Data refreshes hourly during market hours. Next update: 11:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SION showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Peter A Thompson
SELL
2948 shares
2026-04-18
Orbimed Advisors Llc
SELL
2948 shares
2026-04-18
Orbimed Advisors Llc
SELL
52397 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 59 HOLD |
